Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load

Inclusion Criteria Patients may be eligible for this study if they: * Are HIV-positive. * Are more than 18 years old. * Have been receiving their current HAART (2 or more anti-HIV drugs in combination) for more than 6 consecutive months. * Have a CD4 count of 200 cells/microL or more within the 12 months prior to entering the study and 400 cells/microL or more on 2 occasions at least 2 weeks apart within 30 days of entry. * Have never had a viral load higher than 2 million molecules/ml and have had the viral load controlled with HAART to less than 50 molecules/ml on 2 occasions at least 2 weeks apart within 30 days of entry. * Have not had virologic failure on the current HAART regimen. * Have a negative urine pregnancy test within 14 days of entering the study. Exclusion Criteria Patients will not be eligible for this study if they: * Have a current AIDS-defining illness. * Have had failure of the current HAART regimen (viral load higher than 10,000 molecules/ml). * Have a history of using agents affecting the immune system. * Have active uncontrolled heart disease. * Have had IL-2 therapy within 4 weeks of entering the study. * Have received other treatment that affects the immune system within 4 weeks of entry. * Have a history of a cancer requiring chemotherapy. * Have untreated thyroid disease, within 4 weeks of entering the study. * Have uncontrolled allergic disorders or autoimmune diseases, including asthma, inflammatory bowel disease, and psoriasis. * Abuse substances that may interfere with the ability to follow study requirements. * Are allergic to eggs. * Have hepatitis B or hepatitis C. * Are pregnant or breast-feeding. * Work in close contact with canaries, such as a job at breeding farms or bird shops.